Preparation and Evaluation of Chrysin Encapsulated in PLGA-PEG Nanoparticles in the T47-D Breast Cancer Cell Line

Sina Mohammadinejad2,3, Abolfazl Akbarzadeh2, Mohammad Rahmati-Yamchi2, Saeid Hatam5, Saeed Kachalaki4, Sanaat Zohreh1, Nosratollah Zarghami1,2*

Abstract

Background: Polymeric nanoparticles are attractive materials that have been widely used in medicine for drug delivery, with therapeutic applications. In our study, polymeric nanoparticles and the anticancer drug, chrysin, were encapsulated into poly (D, L-lactic-co-glycolic acid) poly (ethylene glycol) (PLGA-PEG) nanoparticles for local treatment. Materials and Methods: PLGA: PEG triblock copolymers were synthesized by ring-opening polymerization of D, L-lactide and glycolide as an initiator. The bulk properties of these copolymers were characterized using 1H nuclear magnetic resonance spectroscopy and Fourier transform infrared spectroscopy. In addition, the resulting particles were characterized by scanning electron microscopy. Results: The chrysin encapsulation efficiency achieved for polymeric nanoparticles was 70% control of release kinetics. The cytotoxicity of different concentration of pure chrysin and chrysin loaded in PLGA-PEG (5-640μM) on T47-D breast cancer cell line was analyzed by MTT-assay. Conclusions: There is potential for use of these nanoparticles for biomedical applications. Future work should include in vivo investigation of the targeting capability and effectiveness of these nanoparticles in the treatment of breast cancer.

Keywords: Triblock copolymer - chrysin - encapsulation - drug encapsulation efficiency

Introduction

Cancer is becoming one of the most public health problems in the world; in 2008, Ferlay et al. estimated the occurrence of new cancer cases about 12.7 million and cancer related death nearly 7.6 million. The most commonly diagnosed cancers in wild world are lung cancer (12.7% of the total), breast cancer (10.9%) and colorectal cancer (9.7%), while the most common cancer related to death are lung cancer (18.2% of the total), stomach cancer (9.7%) and liver cancer (9.2%) (Ferlay et al., 2010). in United States, occurrence of new breast cancer case alone is 29% (Siegel et al., 2012).

Common cancer therapies including surgery, chemotherapy and radiation are often insufficient in treating of cancer diseases, though developing new methods of treatment or cancer therapy are necessary. Some plant medicines have been widely consumed for treatment of various diseases including cancer (Butler, 2004; Koehn and Carter, 2005). Polyphenols account for an important group of plant constituents which contain up to 8,000 different well-known structures (Bravo, 1998). These phenolic components produced by plants are used as secondary metabolites. These components, upon their structure are classified into 10 different types: flavonoids, simple phenols, coumarins, phenolic acids, naphthoquinones, anthaquinones, lignins, isocoumarins, stilbenes and xanthones (Cook and Samman, 1996). The most important class of these phenolic constituents is flavonoids, which is generally safe and shows low toxicity (Samarghandian et al., 2011; Khacha-Ananda et al., 2013). Chrysin (5,7-dihydroxyflavone) is a biologically active flavonoid extracted from plants, propolis and honey (Suganya et al., 2014). Chrysin possesses anti-inflammatory, anti-oxidant and anti-allergic properties (Kadir et al., 2013). Many studies in recent years revealed that chrysin is candidate for cancer therapy in various cancer cell lines by inhibition of cell proliferation and induction of apoptosis (Monasterio et al., 2004; Khoo et al., 2010; Sak, 2014). Chrysin treatment lead to a strong...
increase in p21 and accumulation of cells in G1 phase (Pal-Bhadra et al., 2012). Activate P21 is a cdk (Cyclin-dependent kinases) inhibitor, which lead to apoptosis or cell cycle arrest by reducing in cyclin and cdk(Cai and Dynlacht, 1998).

Cell proliferation is strongly regulated by enormous interactions between molecules (Zhou et al., 2011). The regulatory protein called cyclin when joined to CDKs, promote the cell through the cell cycle (Dickson and Schwartz, 2009; Zeybek et al., 2013). Cyclin D1/ CDK2 and CDK4 transit cell from G1 to S phase, while cyclin E/ CDK2 and cyclin A/ CDK2 respectively, controls entry to S phase and controls S phase progression (Sherr and Roberts, 1999; Zhang et al., 2012). Overexpression of cyclin D1 has been reported to be directly associated with tumorigenicity, poor prognosis and resistance to therapy in several cancer cell lines including breast cancer (Hosokawa and Arnold, 1998; Yu et al., 2001; Fu et al., 2004). Several studies show that cyclin D1 is overexpressed in breast cancer up to 50% (Gillett et al., 1994; Ishii et al., 2006; Sui et al., 2014). Thus, inhibition of cyclin D1 provides an approach to treatment of breast cancer. Although chrysin possesses anti-cancer properties but poor bioavailability of this phenolic compound is an important obstacle for cancer treatment (CAO et al., 2014), which can be due to low absorption, quick metabolism and rapid systemic elimination. One of the approaches to overcome this issue is use of nanoparticles (Yin et al., 2013). Biodegradable polymeric nanocapsules are massively in use in recent years to maintain the quality of many drugs and biologically active compounds. Nanoparticle encapsulation helps to protect therapeutic molecules from being prematurely degraded, enhances their solubility, and provides controlled drug targeting condition (Khalil et al., 2013). PLGA (poly lactic-co-glycolic acid) is polymeric nanoparticle that shows high degree of biocompatibility and Biodegradability as well as safety for human, which is approved by U.S. Food and Drug Administration (FDA) (Alimohammadi and Joo, 2014). Surface modification of PLGA with PEG (polyethylene glycol) could improve permeability and half-life of circulation (Dwivedi et al., 2014). Chrysin to be loaded in PLGA-PEG nanoparticles could increase its bioavailability and efficiency of anti-cancer properties (Braden et al., 2008).

In this study we hypothesize that encapsulation of chrysin with PLGA-PEG have strong effect in cell cycle arrest compared to the effect of pure chrysin and we investigate the efficacy of chrysin loaded in PLGA-PEG in inhibition of cell proliferation and reduction of cyclinD1.

Materials and Methods

Materials

Chrysin, penicillin G, streptomycin, glycolide, PEG (6000), 3(4, 5-dimethylthiazol-2-yi) 2, 5-diphenyl-tetrazolium bromide (MTT), stannous octoate (Sn (Oct) 2), dimethyl sulphoxide (DMSO), dichloromethane (DCM), polyvinyl alcohol (PVA) and D, L-lactide were purchased from Sigma-Aldrich (USA). T47-D breast cancer cell line (code: c203) was obtained from Pasteur Institute of Iran. Trypsin-EDTA, Fetal bovine serum (FBS) and RPMI-1640 were from Gibco, Invitrogen (UK). Primers were purchased from Takapouzist. 2-step RT-PCR kit obtained from vivantis while, Hot TaqEvaGreenPCR Mix and RNX-Plus kit purchased from fromCinnaGen (Iran) and used for cDNA synthesis, real time PCR and total RNA extraction respectively. Real-time PCR was done using Corbett (Rotorgene 6000). Nanodrop spectrophotometer was Bio Photometer. KYKY model EM3200 and Fourier transform infrared spectroscopy (FTIR) Perkin Elmer Series was used for Scanning electron microscopy (SEM) and Infrared spectra respectively.

Synthesis of PLGA-PEG

Synthesis of PLGA-PEG was done through ring open polymerization of glycolide and DL lactide followed by addition of PEG6000. As stated in melt polymerization procedure under vaccume, PEG 6000 and PLGA were co-polymerized in presence of stannous octoate [Sn (Oct) 2] as the catalyst. DL-lactide (2.882g), PEG6000 1.54 g (45% w/w) and glycolide (0.570 g) were melted in bottleneck flask in 140 Celsius degrees under a nitrogen atmosphere. Reaction mixture comprising a 3:1 proportion of DL-lactide to glycolide and 0.05% (w/w) stannous octoate was prepared and heated to 180° C and maintained for four hours.

Chrysin encapsulation with PLGA-PEG

Chrysin were loaded in PLGA-PEG nanoparticle by using s/o/w technique. Briefly, PLGA-PEG (200 mg) was dissolved in dichloromethane (DCM) while pure chrysin (20 mg) was added to this solution and sonicated for 1 minute to yield the s/o primary emulsion. Dimethyl sulphoxide (DMSO) and polyvinyl alcohol (PVA) 1% (1:1) was added to s/o emulsion then sonicated for 1 minute to produces/o/w emulsion. Subsequently solvents of this emulsion were evaporated with rotary evaporator then this emulsion was centrifuged 30 minutes at 10000×g. The drug encapsulation efficiency of chrysin loaded in PLGA-PEG was measured by assessing the supernatant of centrifuged emulsion at 348 nm with spectrophotometer (Braden et al., 2008). Encapsulation efficiency measured by this formula:

\[
\text{Encapsulation} \% = \left( \frac{\text{Drug}_{\text{encapsulated}}}{\text{Drug}_{\text{total}} - \text{Drug}_{\text{filtrate}}} \right) \times 100
\]

FTIR analysis

Functional groups were characterized using FTIR analysis. Figure 1 shows that absorption band at 3509.9 cm\(^{-1}\) is assigned to terminal hydroxyl groups in the copolymer from which PEG homopolymer has been removed. The bands at 3010 cm\(^{-1}\) and 2955 cm\(^{-1}\) are due to C-H stretch of CH\(_2\) and 2885 cm\(^{-1}\) due to C-H stretch of CH. A strong band at 1762.6 cm\(^{-1}\) is assigned to C=O stretch. Absorption at 1186-1089 cm\(^{-1}\) is due to C-O stretch.
SEM analysis

Measurement of size and checking the morphology of nanoparticles were performed by scanning electron microscopy (SEM). The nanographs of PLGA-PEG polymeric nanoparticles (Figure 2A), and Chrysin-loaded PLGA-PEG copolymers nanoparticles are shown. Observing the photograph, it can be seen that the nanoparticles were well aggregated, which was due to the Nano-size of the polymeric nanoparticles about 15 nm. After encapsulation, the size of Chrysin-loaded PLGA-PEG copolymers nanoparticles with PLGA-PEG copolymers, changed to 20-75 nm and dispersion of the particles was greatly improved (Figure 2B), which can be explained by the electrostatic repulsion force and steric hindrance between the copolymer chains on the encapsulated polymeric nanoparticles. The samples were coated with gold particles.

Cell culture

T47-D breast cancer cell line were cultured in RPMI-1640 medium with 10% FBS and incubated at 37°C and 5% CO₂. The RPMI-1640 also has streptomycin (50 μg/mL), penicillin G (100U/mL) and NaHCO₃ (2mg/mL).

Cell viability analysis

MTT assay was done to measure T47-D cell viability. 10000 cell/well were seeded on 96-well plate and allowed them to attach for 24 h. Afterward cells were treated with different concentration of pure and Nano chrysin (5-640 μM) for 24, 48 and 72h. For each concentration triplicate were chosen and control received same amount of solvent (DMSO). After 24, 48 and 72 h medium were removed from all well while, 200 μL medium and 50 μL MTT solution were added to each wells and incubated for 4 h at 37°C. Then mixture of MTT solution and medium discarded from all wells and MTT crystals were dissolved by adding 200 μL DMSO and 50 μL Sorenson’s buffer. The viability of the cells was calculated by this formula:

\[
\text{Cell viability} \% = \left( \frac{\text{absorbance of experimental wells}}{\text{absorbance of control wells}} \right) \times 100
\]

RNA extraction, cDNA synthesis and real-time PCR

T47-D cells were treated with different concentrations of pure and Nano chrysin (34, 54 and 74 μM) for 24 h. After drug exposure time, according to the instructions of the RNX-Plus manufacturer total RNA were extracted. Nanodrop was proved the purity and quantity of total RNA. After the integrity of total RNA was examined by using electrophoresis, complementary DNA (cDNA) was synthesis by 2-step RT-PCR kit according to the instructions of the manufacturer. Next Quantitative real-time PCR technique was used to determine cyclin D1 expression levels and Hot TaqEvaGreenqPCR Mix used following the instructions of the manufacturer. Sequence of forward and reverse primers for cyclin D1 were, F: 5’-TGCCCTCCTGTGCCACAGATG-3’, R: 5’-CTCTGGAGAGGAAGCGTGTGA-3’ and primers for β-actin, F: 5’-TCCCTGGAGAAGAGCTACG-3’, R: 5’-GTAGTTTCGTGGATGCCACA-3’. The samples were incubated in following order (Table 1). Relative cyclin D1 expression levels was normalized by housekeeping gene (β-actin) and relative expression of cyclin D1 calculated by this formula:

\[
\text{Relative gene expression} = \frac{E(\text{target})^{\Delta C P(\text{target})}}{E(\text{reference})^{\Delta C P(\text{reference})}}
\]

Table 1. The Raction Mixtures Incubated for Real-Time PCR in Following Order

<table>
<thead>
<tr>
<th>step</th>
<th>Temperature</th>
<th>Time</th>
<th>Number of cycle</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial denaturation</td>
<td>95°C</td>
<td>15 minutes</td>
<td>1 cycle</td>
</tr>
<tr>
<td>Denaturation</td>
<td>95°C</td>
<td>15 seconds</td>
<td>45 cycles</td>
</tr>
<tr>
<td>Annealing</td>
<td>59°C</td>
<td>30 seconds</td>
<td></td>
</tr>
<tr>
<td>Elongation</td>
<td>72°C</td>
<td>20 seconds</td>
<td></td>
</tr>
<tr>
<td>Melting</td>
<td>59-95°C</td>
<td>5 seconds for each degrees</td>
<td>1 cycle</td>
</tr>
</tbody>
</table>

**Figure 1. FTIR Result show Presence of Chrysin PLGA-PEG Nanoparticle**

**Figure 2. SEM picture show (a) the size PLGA-PEG and (b)drug loaded in PLGA-PEG nanoparticle**
Data analysis and statistics

GraphPad.Prism.6.01. was employed for all data analysis and plotting graphs. Statistical analysis was performed by ANOVA test (by one-way analysis of variance). The result was assumed of statistical importance when/if p-value was smaller than 0.05.

Results

Encapsulation efficiency

Analysis of supernatant of chrysin loaded in PLGA-PEG showed that chrysin were encapsulated via PLGA-PEG nanoparticle in 98.6% encapsulation efficiency. Success in PLGA-PEG synthesis by open ring copolymerization was confirmed by SEM (Figure2). The results of FTIR verified present of chrysin in PLGA-PEG.

Cell viability assay

The cytotoxicity of different concentration of pure chrysin and chrysin loaded in PLGA-PEG (5-640μM) on T47-D breast cancer cell line were analyzed by MTT-assay technique. These serial dilution of pure and Nano chrysin were treated on T47-D for 24, 48 and 72 h and results suggested that pure chrysin and chrysin loaded in PLGA-PEG could inhibit cell proliferation by dose dependent manner. The IC\textsubscript{50} value for 24 h treatments were 54.56 for pure chrysin and 48.72 for chrysin loaded in PLGA-PEG (Figure 3A). IC\textsubscript{50} value of 48 h were 46.74 and 44.78 respectively for pure and Nano chrysin (Figure 3B) while for 72 h treatment of pure chrysin and Nano chrysin IC\textsubscript{50} value were 40.28 and 37.54 respectively (Figure 3C). These results showed that PLGA-PEG nanoparticle could improve the efficiency of chrysin in cell growth inhibition (Table 2).

Quantitative real-time PCR

The levels of cyclin D1 expression was measured by real-time PCR. Cyclin D1 mRNA levels were normalized by β-actin (housekeeping gene). Different concentration of pure chrysin (34, 54 and 74 μM) for 24 treatment decreased relative cyclin D1 expression in .78±.04, .37±.03 and 24±.02 respectively. Whereas chrysin loaded in PLGA-PEG nanoparticle in same concentration reduced further relative mRNA expression of cyclin D1 in .56±.04, 23±.03 and .16±.03 for 34, 54 and 74 μM respectively (Figure 4). The results suggested that chrysin loaded in PLGA-PEG had better effect in decline cyclin D1 expression rather than pure chrysin.

Discussion

Breast cancer is one of the most common types of cancer with >1,300,000 cases and 450,000 mortalities...
Preparation and Evaluation of Chrysin Encapsulated in PLGA-PEG Nanoparticles inn T47-D Breast Cancer Cells


DOI: http://dx.doi.org/10.7314/APJCP.2015.16.9.3753

Acknowledgements

Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, for all support provided. This work is funded by 92/20 grant of Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

References


